Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a cancer drug stop transplant complications before they start?

NCT ID NCT06271616

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 10, 2026 · Updated 20 times

Summary

This study tests whether the drug ibrutinib can prevent chronic graft-versus-host disease (GVHD) in people who have received a donor stem cell transplant. Chronic GVHD is a common complication where donor cells attack the patient's body. Ibrutinib blocks a protein that activates certain immune cells involved in GVHD. The trial enrolls 40 adults who are 50 to 110 days post-transplant and aims to see if the drug reduces the risk of moderate to severe chronic GVHD.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHATIC SYSTEM NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic in Florida

    RECRUITING

    Jacksonville, Florida, 32224-9980, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

CHRONIC GRAFT VERSUS HOST DISEASE HEMATOPOIETIC AND LYMPHATIC SYSTEM NEOPLASM